Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8837096 | 0.77 | CA12 (0.40) | TDP1CYP2C9CYP2C19 | |
| SCHEMBL6137087 | 0.74 | TDP1 (0.44) | TDP1CYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL10506433 | 0.71 | TDP1 (0.39) | TDP1CYP2C9CYP2C19 | |
| SCHEMBL3726840 | 0.69 | TDP1 (0.35) | TDP1CYP2C9CYP2C19 | |
| SCHEMBL2182907 | 0.68 | TDP1 (0.82) | TDP1CYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL28169879 | 0.67 | TDP1 (0.39) | TDP1CYP2C9CYP2C19 | |
| SCHEMBL9746468 | 0.67 | CYP2C9 (0.46) | TDP1CYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL19703499 | 0.67 | CASP2 (0.41) | TDP1CYP2C9CYP2C19 | |
| SCHEMBL7682093 | 0.66 | TDP1 (0.64) | TDP1CYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL18576277 | 0.66 | TDP1 (0.78) | TDP1CYP2C9CYP2C19PRMT3CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | TDP1 3469/4885CYP2C9 4461/4885CYP2C19 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.